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Summary The expression of sialosyl-Tn (STn) antigen was evaluated by immunohistochemistry in primary
gastric cancers. Twenty-one of 31 (68%) gastric cancers expressed STn, regardless of tumour location, stage or
histological type. Eighty-one per cent of patients with STn-positive tumours died of their disease or had
recurrent cancer, compared with 20% of patients with STn-negative tumours (P<0.002). STn may be a useful
prognostic marker in patients with gastric cancer.
Many tumour markers now coming into clinical use for
diagnosing gastrointestinal cancers are carbohydrate-
associated antigens. One such marker, sialosyl-Tn (STn), is a
carbohydrate-associated antigen found on mucin-type glyco-
proteins (Hakomori, 1989). Using monoclonal antibody
(MAb) TKH2, specific for the STn epitope (Kjeldsen et al.,
1988), we previously observed that in colonic tissues this
antigen was not expressed by normal mucosa, but expression
increased in premalignant lesions (adenomas, chronic
ulcerative colitis) and approached 87-90% sensitivity in
colon cancer tissues (Itzkowitz et al., 1989, 1990, 1992; Thor
et al., 1989). Furthermore, in colon cancer tissues, STn ex-
pression was found to be an independent predictor of out-
come such that patients with STn-negative tumours had an
excellent overall and disease-free survival regardless of
tumour stage (Itzkowitz et al., 1990).
Little is known about STn expression in normal or malig-
nant gastric tissues. The purpose of this investigation was to
shed light on STn distribution in normal and abnormal
gastric tissue, and correlate STn expression with survival in
patients with gastric cancer.
Materials and methods
Clinical material
We studied 31 patients who underwent surgical resection for
gastric cancer between 1974 and 1984 in whom pathological,
clinical and long-term outcome data as well as pathology
specimens were available. Eleven patients received no post-
surgical therapy, 15 patients were treated with adjuvant
chemotherapy after curative resection and five patients
received chemotherapy for unresectable or metastatic disease.
Deaths not attributed to gastric cancer were verified by
clinical follow-up and imaging studies.
Table I lists the clinicopathological data on the patients.
The 11 non-caucasian patients included four black, four
Hispanic and three oriental individuals. Tumour size and the
presence of involved lymph nodes were known for all sub-
jects, although complete staging information was not
available for some patients. Five patients had uninvolved
lymph nodes; all others had tumour which spread to lymph
nodes or other metastatic sites. The mean follow-up period
was 46 months (range 9-168 months).
Archival paraffin-embedded tissues were retrieved from
Pathology Department files, and sections 5 jsm thick were
prepared for immunohistochemical staining. One represen-
Table I Correlation of sialosyl-Tn expression
clinicopathological features of tumours
with
Total STn+ STn-
(n =31) (n =21) (n =10)
Age (mean ± s.d.) 65+ 12 63.5+ 11.8 67.6± 12.8
Sex
Male 15 9 (43%) 6 (60%)
Female 16 12 (57%) 4 (40%)
Race
White 20 13 (62%) 7 (70%)
Non-white 11 8 (38%) 3 (30%)
Site
Cardia 7 4 (19%) 3 (30%)
Antrum, body 23 16 (76%) 7 (70%)
Unspecified 1 1 (5%)
Stage
T, 2 1 (5%) 1 (10%)
T2 11 *6 (29%) ***5 (50%)
T3 14 *11 (52%) 3 (30%)
T4 3 2 (10%) 1 (10%)
Unspecified 1 1 (5%)
Histological type
Well differentiated 11 8 (38%) 3 (30%)
Moderately differentiated 8 5 (24%) 3 (30%)
Poorly differentiated 8 4 (21%) 4 (40%)
Mucinous; signet ring 4 4 (21%)
Chemotherapy
None 11 9 (43%) 2 (20%)
Adjuvant 15 8 (38%) 7 (70%)
Advanced disease 5 4 (21%) 1 (10%)
Each asterisk represents one node-negative patient.
tative tumour block was selected, with efforts made to in-
clude superficial and deep portions of the tumour. Whenever
possible, a block of histologically normal gastric mucosa
several cm away from the tumour was also examined.
Immunohistochemistry
Monoclonal antibody TKH2 (IgGI), which specifically reacts
with the sialosyl-Tn antigen (Kjeldsen et al., 1988), was
kindly provided by Dr Sen-itiroh Hakomori (The Biomem-
brane Institute, Seattle, WA, USA).
Slides were stained using previously described methods
(Itzkowitz et al., 1990). Negative controls consisted of sub-
stituting mouse IgGl for MAb TKH2, which resulted in no
staining.
Scoring ofantigen expression
Slides were interpreted for STn antigen expression without
knowledge of clinicopathological or outcome data. Scoring
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was performed by examining all low-power optical fields
(10 x objective) containing tumour and estimating the
percentage of antigen-positive cells. A tumour was considered
positive if more than 5% of cells expressed STn antigen.
Results
Sialosyl-Tn expression in normal gastric mucosa and intestinal
metaplasia
STn antigen was not expressed by cells of normal gastric
mucosa except for parietal cells, which exhibited STn expres-
sion in intracellular canalicular membranes (Figure la).
Mucus-secreting cells of foveolar epithelium, deep gastric
glands, and mucous neck cells were all devoid of STn expres-
sion. In sharp contrast, the mucin in goblet cell vacuoles
from cases of intestinal metaplasia (n = 13) exhibited strong
STn expression (Figure lb).
STn expression in gastric cancer
Of the 31 gastric cancers studied, 21 (68%) expressed STn
antigen. As indicated in Table I, there was no difference in
the mean age, sex, or race of patients who had STn-positive
tumours compared with those with STn-negative tumours.
Likewise, the location of the cancer within the stomach did
not influence its tendency to express STn antigen. Antigen
expression was independent of tumour size, although 62% of
the STn-positive tumours were large (T3 and T4 lesions)
compared with 40% of STn-negative tumours. Of the five
patients with uninvolved lymph nodes, three had STn-
negative primary carcinomas. Expression of STn was
independent of the histological type of the tumour, but all
four of the signet ring carcinomas were STn- positive. The
frequency of chemotherapy was not significantly different in
patients with STn-positive vs STn-negative tumours, although
slightly more patients with STn-negative tumours received
adjuvant chemotherapy.
Correlation ofSTn expression with clinical outcome
An adverse outcome, defined as death from disease or disease
recurrence, occurred in 17/21 (81%) patients with STn-
positive tumours compared with only 2/10 (20%) patients
with STn-negative tumours (P<0.002; chi-square) (Table II).
Of the 17 patients with STn-positive tumours and an adverse
outcome, only two are still alive. Among the ten patients
with STn-negative tumours, eight are either alive and well or
died of causes unrelated to their tumour. The other two
individuals with STn-negative tumours died of their disease.
One of them was an 80-year-old man with a moderately
differentiated cancer of the gastric body, stage T3 N1 MO, with
extensive involvement of perigastric fat, who underwent
adjuvant therapy with 5-FU/methyl-CCNU but died 9
months later. The other patient was a 49-year-old woman
who underwent distal subtotal gastrectomy for a stage
T4 N, Mo poorly differentiated adenocarcinoma involving the
perigastric fat and distal margin of resection and died 25
months later despite adjuvant radiotherapy and FAME (5-
fluorouracil, adriamycin, methyl-CCNU). In both the sialosyl-
Tn-positive and sialosyl-Tn-negative groups, all five patients
without lymph node metastases (asterisks in Tables I and II)
were among the individuals with a favourable outcome.
Of the 11 patients with T2 lesions, none ofthe five that had
STn-negative tumours died of their disease, whereas four of
the six with STn-positive tumours did. Of the 14 patients
with T3 lesions, one of three patients with STn-negative
tumours died of the disease, whereas 9 of 11 patients with
STn-positive tumours died of the disease. All three patients
with T4 tumours died of gastric cancer, whereas neither of
the two patients with T, tumours did.
The clinical status of patients according to degree of
sialosyl-Tn expression is depicted in Figure 2. Among the
patients with STn-positive tumours, 15/21 (71%) died of
a
b
Figure 1 a, Sialosyl-Tn expression in parietal cells of normal
gastric mucosa (original magnification 50 x). b, Sialosyl-Tn exp-
ression in intestinal metaplasia of the stomach. Glands that have
undergone intestinal metaplasia demonstrate sialosyl-Tn expres-
sion in goblet cell vacuoles and gland secretions. The surrounding
normal gastric glands do not express sialosyl-Tn antigen (original
magnification 25 x).
Table II Outcome of patients according to sialosyl-Tn status
Total STn+ STn-
Outcome (n =31) (n =21) (n = 10)
Adverse
Dead, with disease 17 15 (71%) 2 (20%)
Alive, recurrence 2 2 (10%)
Favourable
Dead, NED 8 *2 (10%) ***6 (60%)
Alive, NED 3 *1 (5%) 2 (20%)
Dead, unspecified 1 1 (5%)
Each asterisk represents one node-negative patient. NED. No
evidence of disease.
their disease, in all cases within 5 years from the time of
diagnosis. The actual level of STn expression, however, did
not correlate with the duration of survival. There were two
patients with STn-positive cancers who developed recurrent
disease. One patient had a moderately differentiated car-
cinoma of the antrum, stage T2 N2 Mo, and underwent distal
gastrectomy followed by 5-FU/methyl-CCNU therapy and
developed a recurrence at the anastomosis 75 months later.
The other patient had a moderately differentiated adenocar-
cinoma of the gastric body, stage T, N1 MO, underwent sub-
total distal gastrectomy without adjuvant chemotherapy, and
18 months later was found to have another moderately
differentiated carcinoma of the cardia, stage T2NoMo. Fol-
lowing resection of the second lesion, this patient has
remained free of disease for 14 years. Only one patient in the
STn-positive group is alive and well without tumour recur-
rence. This tumour was a well-differentiated, antral lesion,SIALOSYL-Tn ANTIGEN IN GASTRIC CANCER PROGNOSIS 615
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Figure 2 Survival of patients according to sialosyl-Tn expres-
sion. Symbols represent death due to disease (+), death without
evidence of disease (0), death from unspecified cause (A), alive
and well (0), alive with disease recurrence (0).
stage T3 No Mo, treated by distal gastrectomy and adjuvant
5-FU/methyl-CCNU which expressed STn only focally in
approximately 40% of the tumour cells, and the patient has
survived 57 months.
Among the patients with STn-negative tumours, 6 of 10
(60%) have survived 5 years or more (Figure 2). Of the eight
deaths in this group, only two were attributable to gastric
cancer.
Discussion
Sialosyl-Tn is a simple mucin-type carbohydrate antigen
which has a very restricted distribution in the body. In fact,
only goblet cells of the small intestine, parietal cells of the
stomach, testicular Leydig cells and some endothelial cells
express STn (Kjeldsen et al., 1988). On the other hand,
adenocarcinomas of several epithelial organs frequently ex-
press STn. Moreover, expression of STn by colon cancers
and ovarian cancers has been associated with a poor survival
(Itzkowitz et al., 1990; Kobayashi et al., 1992). This suggests
that STn expression by cancer cells plays an important role
in the biology of the tumour.
In the present study, 68% of primary gastric adenocar-
cinomas expressed STn. This is consistent with earlier studies
reporting the prevalence of STn expression in gastric cancer
tissues as ranging between 71 and 100% (Ohuchi et al., 1986;
Thor et al., 1986; Kjeldsen et al., 1988; Nakasaki et al., 1989;
David et al., 1992). The tendency for a tumour to express
STn in our study did not depend upon patient age, sex,
tumour location, tumour stage or degree of differentiation.
Likewise, Ohuchi et al. (1986) found no correlation between
STn expression and degree ofdifferentiation, and David et al.
(1992) found no association between STn expression and
histological type, growth pattern, lymphoid infiltrate, lymph
node metastasis, venous invasion and ploidy status in gastric
cancers. They thus concluded that STn may not be a marker
of tumour aggressiveness. However, as we have previously
noted in colon cancer (Itzkowitz et al., 1990), and now report
in gastric cancer, STn expression does not have to correlate
with histopathological features in order to serve as a useful
marker of an adverse outcome. In fact, for a new marker of
prognosis to enhance upon existing prognostic pathological
features it should be independent of those features.
STn has been detected at abnormally high levels in the
serum of 28-59% of gastric cancer patients (Farinati et al.,
1989; Heptner et al., 1989; Correale et al., 1991; Guadagni et
al., 1991, 1992; Motoo et al., 1991), and in this disease STn
(defined as CA72-4 antigen) is a more sensitive and specific
marker than either carcinoembryonic antigen or CA19-9
(Heptner, et al., 1989; Guadagni et al., 1992). Moreover,
elevated circulating STn levels may predict the development
of recurrent gastric cancer after surgical resection more
accurately than CEA (Guadagni et al., 1991, 1992). It seems,
however, that only late-stage gastric carcinomas are
associated with elevated serum STn levels (Guadagni et al.,
1991, 1992).
It is not yet clear why patients with STn-positive tumours
should have a worse prognosis than those with STn-negative
tumours. Sialomucins have been shown in colon cancer
model systems to be important in metastasis (Bresalier et al.,
1991), and most metastases of gastric cancer express STn
(David et al., 1992). In addition, mucins bearing STn antigen
can mediate inhibition of natural killer cell cytotoxicity,
thereby providing a mechanism for immune escape (Ogata et
al., 1992).
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